Endometriosis Major Markets, Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2034

All the vital news, analysis, and commentary curated by our industry experts.

$17995

Buy Report Download FREE Resources

Published: June 24, 2025 Report Code: GDHC316PIDR-7M-ST

Report Overview
Key Players
Table of Contents
Table
Figures

This report covers the 7MM (US, France, Germany, Italy, Spain, UK, Japan) and provides an Excel-based forecast model for the Endometriosis market through 2034.

GlobalData estimates the 2024 sales for the endometriosis market at approximately $938.0 million across the 7MM, encompassing the US, the 5EU, and Japan. By 2034, GlobalData expects the overall market to grow at a compound annual growth rate (CAGR) of 10.3% to reach sales of $2.5 billion over the 10-year period. The US market will grow fastest, with a 13.2% CAGR, compared to a decline of 0.7% in the 5EU and growth of 1.0% in Japan. At the end of 2034, the US will contribute approximately 88.4% of global sales. The higher sales in the US relative to the other two regions can be attributed to the greater diagnosed prevalence of endometriosis in the US and the higher price of drugs in the US compared to other global markets.
Major drivers of the endometriosis market during the forecast period will include:
• The launch of Kissei Pharmaceutical’s Yselty (linzagolix), which is currently marketed in the in the US and Japan
• The launch of Hope Medicine’s HMI-115 in the US and Fuji Pharma’s Alyssa (drospirenone + estetrol) in Japan
• Continual improvements with disease awareness, leading to an increase in diagnoses
• Improvements in non-invasive diagnostic methods, such as the utilization of biomarkers, which should further increase the number of early diagnoses
Major barriers to the growth of the endometriosis market during the forecast period are as follows:
• The endometriosis market boasts many off-label medications and is still highly genericized, presenting a stiff barrier for novel therapy entrants.
• The shrinking female population ages 12–54 years in the 5EU and Japan will dampen the extent of growth in diagnosed endometriosis cases.

Scope

Overview of endometriosis, including epidemiology, symptoms, diagnosis, and disease management.

Annualized endometriosis therapeutics market revenue, cost of therapy per patient, and treatment usage patterns forecast from 2024 to 2034.

Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping, and implications of these factors for the endometriosis therapeutics market.

Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for endometriosis treatment. The most promising candidates in late-stage development are profiled.

Analysis of the current and future market competition in the global endometriosis therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to Buy

Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.

Develop business strategies by understanding the trends shaping and driving the 7MM endometriosis therapeutics market.

Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the 7MM endometriosis therapeutics market in the future.

Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.

Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.

Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

AstraZeneca
Abbvie
Debiopharma
Myovant Science
Abbott
Neurocine Biosciences
Sumitomo
Ipsen
Sanofi
Hope Medicine
Bayer
Pfizer
Kissei
ASKA Pharmacutical
Gedeon Richter

List of Contents 2

List of Tables 5

List of Figures 5

1 Endometriosis: Executive Summary 7

1.1 The endometriosis market will exhibit considerable growth from 2024 to 2034 8

1.2 Key players will continue their competitive position in the endometriosis market over the forecast period 9

1.3 Current therapies leave significant unmet needs in the endometriosis market 11

1.4 Late-stage pipeline drugs entering the endometriosis market are poised to drive growth 12

1.5 What do physicians think? 14

2 Introduction 15

2.1 Catalyst 15

2.2 Related reports 15

2.3 Upcoming reports 15

3 Disease Overview 16

3.1 Etiology and pathophysiology 16

3.1.1 Etiology 17

3.1.2 Pathophysiology 21

3.2 Classification or staging systems 23

4 Epidemiology 24

4.1 Disease background 24

4.2 Risk factors and comorbidities 26

4.3 Global and historical trends 28

4.4 Forecast methodology 29

4.4.1 Sources 29

4.4.2 Forecast assumptions and methods 36

4.4.3 Forecast assumptions and methods: diagnosed incident cases of endometriosis – 7MM 36

4.4.4 Forecast assumptions and methods: diagnosed prevalent cases of endometriosis 39

4.4.5 Forecast assumptions and methods: laparoscopy confirmation status for the diagnosed incident cases of endometriosis 41

4.4.6 Forecast assumptions and methods: laparoscopy confirmation status for the diagnosed prevalent cases of endometriosis 41

4.4.7 Forecast assumptions and methods: diagnosed prevalent cases of endometriosis by ASRM stage 44

4.4.8 Forecast assumptions and methods: diagnosed prevalent cases of endometriosis by phenotype 45

4.4.9 Forecast assumptions and methods: diagnosed prevalent cases of endometriosis by comorbidities 47

4.5 Epidemiological forecast for endometriosis (2024–34) 49

4.5.1 Diagnosed incident cases of endometriosis 49

4.5.2 Age-specific diagnosed incident cases of endometriosis 50

4.5.3 Laparoscopy confirmation status for the diagnosed incident cases of endometriosis 51

4.5.4 Diagnosed prevalent cases of endometriosis 52

4.5.5 Age-specific diagnosed prevalent cases of endometriosis 53

4.5.6 Laparoscopy confirmation status for the diagnosed prevalent cases of endometriosis 54

4.5.7 Diagnosed prevalent cases of endometriosis by ASRM stage 55

4.5.8 Diagnosed prevalent cases of endometriosis by phenotype 56

4.5.9 Diagnosed prevalent cases of endometriosis by comorbidities 57

4.6 Discussion 57

4.6.1 Epidemiological forecast insight 57

4.6.2 Limitations of the analysis 58

4.6.3 Strengths of the analysis 59

5 Disease Management 60

5.1 Diagnosis and treatment overview 60

5.2 KOL insights on disease management 62

6 Current Treatment Options 65

6.1 Overview 65

7 Unmet Needs and Opportunity Assessment 69

7.1 Overview 69

7.2 Non-invasive diagnostics 70

7.3 Disease awareness and education of medical professionals 72

7.4 More effective drugs with long-term safety and tolerability 74

7.5 Non-hormonal therapies 75

7.6 Better understanding of the disease etiology and pathophysiology 77

8 R&D Strategies 79

8.1 Overview 79

8.1.1 Exploring regenerative and precision medicine 79

8.1.2 Development of novel non-hormonal therapies 79

8.2 Clinical trials design 80

8.2.1 Pain scales 80

8.2.2 Quality of life assessment as an efficacy tool 80

9 Pipeline Assessment 82

9.1 Overview 82

9.2 Promising drugs in clinical development 83

10 Pipeline Valuation Analysis 85

10.1 Overview 85

10.2 Competitive assessment 86

11 Current and Future Players 88

11.1 Overview 88

11.2 Deal-making trends 90

12 Market Outlook 91

12.1 Global markets 91

12.1.1 Forecast 91

12.1.2 Drivers and barriers – global (7MM) issues 92

12.2 US 93

12.2.1 Forecast 93

12.2.2 Key events 94

12.2.3 Drivers and barriers 94

12.3 5EU 94

12.3.1 Forecast 94

12.3.2 Key events 95

12.3.3 Drivers and barriers 96

12.4 Japan 97

12.4.1 Forecast 97

12.4.2 Key events 98

12.4.3 Drivers and barriers 98

13 Appendix 99

13.1 Bibliography 99

13.2 Abbreviations 110

13.3 Methodology 111

13.3.1 Forecasting methodology 111

13.4 Primary research – KOLs interviewed for this report 112

13.4.1 KOLs 112

13.5 Primary research – prescriber survey 113

13.6 About the Authors 114

13.6.1 Analyst 114

13.6.2 Therapy Area Director 114

13.6.3 Epidemiologist 114

13.6.4 Reviewers 115

13.6.5 Vice President of Disease Intelligence and Epidemiology 116

13.6.6 Global Head of Pharma Research, Analysis, and Competitive Intelligence 117

About GlobalData 118

Table

Table 1: Endometriosis: key metrics in the 7MM 6

Table 2: Role of the different theories in the pathogenesis of endometriosis 17

Table 3: Classifications of endometriosis 22

Table 4: Risk factors and comorbidities for endometriosis 26

Table 5: The most used guidelines by country 60

Table 6: Top 10 deals by value, 2020–25 89

Table 7: Endometriosis market – global (7MM) drivers and barriers, 2024–34 91

Table 8: Key events impacting sales for endometriosis in the US, 2024–34 93

Table 9: Endometriosis market – drivers and barriers in the US, 2024–34 93

Table 10: Key events impacting sales for endometriosis in the 5EU, 2024–34 94

Table 11: Endometriosis market – drivers and barriers in the 5EU, 2024–34 95

Table 12: Key events impacting sales for endometriosis in Japan, 2024–34 97

Table 13: Endometriosis market – drivers and barriers in Japan, 2024–34 97

Table 14: High-prescribing physicians (non-KOLs) surveyed, by country 112

Figures

Figure 1: Global sales forecast by country for endometriosis in 2024 and 2034 9

Figure 2: Analysis of the company portfolio gap in endometriosis during the forecast period 10

Figure 3: Competitive assessment of the late-stage pipeline agents that GlobalData expects to be licensed for the treatment of endometriosis during the forecast period 13

Figure 4: Roles of estrogen receptor α and estrogen receptor β in normal endometrium and endometrial lesions 17

Figure 5: Endometrial lesions of varying depth 17

Figure 6: Sources of estradiol in endometriosis tissue and targets of the current medical therapy 20

Figure 7: 7MM, diagnosed incidence of endometriosis (cases per 100,000 population), women, ages 12–54 years, 2024 28

Figure 8: 7MM, diagnosed prevalence of endometriosis (%), women, ages 12–54 years, 2024 29

Figure 9: 7MM, sources used and not used to forecast the diagnosed incident cases of endometriosis 30

Figure 10: MM, sources used and not used to forecast the diagnosed prevalent cases of endometriosis 31

Figure 11: 7MM, sources used to forecast the laparoscopy confirmation status for the diagnosed prevalent cases of endometriosis 32

Figure 12: 7MM, sources used to forecast the diagnosed prevalent cases of endometriosis by ASRM stage 33

Figure 13: 7MM, sources used to forecast the diagnosed prevalent cases of endometriosis by phenotype 34

Figure 14: 7MM, sources used to forecast the diagnosed prevalent cases of endometriosis by comorbidities 35

Figure 15: 7MM, diagnosed incident cases of endometriosis, N, women, ages 12–54 years, 2024 49

Figure 16: 7MM, diagnosed incident cases of endometriosis by age, N, women, 2024 50

Figure 17: 7MM, laparoscopy confirmation status for the diagnosed incident cases of endometriosis, N, women, ages 12–54 years, 2024 51

Figure 18: 7MM, diagnosed prevalent cases of endometriosis, N, women, ages 12–54 years, 2024 52

Figure 19: 7MM, diagnosed prevalent cases of endometriosis by age, N, women, 2024 53

Figure 20: 7MM, laparoscopy confirmation status for the diagnosed prevalent cases of endometriosis, N, women, ages 12–54 years, 2024 54

Figure 21: 7MM, diagnosed prevalent cases of endometriosis by ASRM stage, N, women, ages 12–54 years, 2024 55

Figure 22: 7MM, diagnosed prevalent cases of endometriosis by phenotype, N, women, ages 12–54 years, 2024 56

Figure 23: 7MM, diagnosed prevalent cases of endometriosis by comorbidities, N, women ages 12–54 years, 2024 57

Figure 23: Sample endometriosis treatment algorithm 61

Figure 25: Unmet needs and opportunities in endometriosis 70

Figure 26: Overview of the development pipeline in endometriosis 82

Figure 27: Key late-stage trials for the promising pipeline agents that GlobalData expects to be licensed for endometriosis in the 7MM during the forecast period 83

Figure 28: Competitive assessment of the promising pipeline agents that GlobalData expects to be licensed for endometriosis in the 7MM during the forecast period 84

Figure 29: Competitive assessment of the marketed and pipeline drugs benchmarked against the GnRH antagonist, Orilissa 86

Figure 30: Competitive assessment of the marketed and pipeline drugs benchmarked against the hormonal contraceptives 87

Figure 31: Competitive assessment of the marketed and pipeline drugs benchmarked against the subcutaneous agent, Zoladex 87

Figure 32: Analysis of the company portfolio gap in endometriosis during the forecast period 89

Figure 33: Global (7MM) sales forecast by country for endometriosis in 2024 and 2034 92

Figure 34: Sales forecast by class for endometriosis in the US in 2024 and 2034 93

Figure 35: Sales forecast by class for endometriosis in the 5EU in 2024 and 2034 95

Figure 36: Sales forecast by class for endometriosis in Japan in 2024 and 2034 97

Endometriosis Major Markets, Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2034 standard reports

Currency USD

Single User

$17,995

Can be used by individual purchaser only

Undecided about purchasing this report?

Enquire Before Buying Download FREE Resources

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Sample Report

Endometriosis Major Markets, Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2034 was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

Assess the relevance of the report
Evaluate the quality of the report
Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise. The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS

Related reports

View more Endometriosis reports

Pharmaceuticals

New

Reflux Esophagitis (Gastroesophageal Reflux Disease): Market View, Current and Future…

Pharmaceuticals

New

Hepatocellular Carcinoma (HCC): Epidemiology Report and Forecast to 2035

Pharmaceuticals

New

Overweight and Obesity: Epidemiology Report and Forecast to 2035

Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Endometriosis Major Markets, Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2034 in real time.

Access a live Endometriosis Major Markets, Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2034 dashboard for 12 months, with up-to-the-minute insights.
Fuel your decision making with real-time deal coverage and media activity.
Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.

Tell me more

Reports

Reports by Sector

Report Type

Endometriosis Major Markets, Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2034

Scope

Reasons to Buy

Table of Contents

Table

Figures

Undecided about purchasing this report?

Get in touch to find out about multi-purchase discounts

Sample Report

Below is a sample report to understand what you are buying

Related reports